Electric pulses plus chemo aimed at rare tumor, but study pulled
NCT ID NCT06660121
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study planned to test electrochemotherapy (ECT) with bleomycin in people with desmoid fibromatosis, a non-cancerous but locally aggressive tumor. The goal was to see if the treatment could shrink the tumor and improve symptoms like pain. However, the study was withdrawn before any patients were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bleomycin
- What this could lead to
- If successful, this approach could offer a new localized treatment option for desmoid fibromatosis when surgery or other therapies are not possible.
- What could go wrong
- The study was withdrawn before enrolling any participants, so no results are available. The treatment involves chemotherapy and electrical pulses, which carry risks like pain, infection, or tissue damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DESMOID FIBROMATOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IRCCS Istituto Ortopedico Rizzoli
Bologna, 40136, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cancer drug shows promise in slowing rare tumor growth
- Desmoid tumor study: just watching may be enough
- No-Chemo embolization tackles rare desmoid tumors
- Promising drug may shrink rare tumors in kids without surgery
- Immunotherapy duo takes on rare tumors
- Massive childhood cancer registry launches to unlock better treatments